Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies

Sci Adv. 2022 Feb 4;8(5):eabm6247. doi: 10.1126/sciadv.abm6247. Epub 2022 Feb 2.


One-fifth of meningiomas classified as benign by World Health Organization (WHO) histopathological grading will behave malignantly. To better diagnose these tumors, several groups turned to DNA methylation, whereas we combined RNA-sequencing (RNA-seq) and cytogenetics. Both approaches were more accurate than histopathology in identifying aggressive tumors, but whether they revealed similar tumor types was unclear. We therefore performed unbiased DNA methylation, RNA-seq, and cytogenetic profiling on 110 primary meningiomas WHO grade I and II). Each technique distinguished the same three groups (two benign and one malignant) as our previous molecular classification; integrating these methods into one classifier further improved accuracy. Computational modeling revealed strong correlations between transcription and cytogenetic changes, particularly loss of chromosome 1p, in malignant tumors. Applying our classifier to data from previous studies also resolved certain anomalies entailed by grouping tumors by WHO grade. Accurate classification will therefore elucidate meningioma biology as well as improve diagnosis and prognosis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA Methylation
  • Humans
  • Meningeal Neoplasms* / diagnosis
  • Meningeal Neoplasms* / genetics
  • Meningeal Neoplasms* / pathology
  • Meningioma* / diagnosis
  • Meningioma* / genetics
  • Meningioma* / pathology
  • Plant Extracts
  • Prognosis


  • Plant Extracts